thiophenes has been researched along with olaparib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JL; Lawrence, TS; Liu, E; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Vance, S; Zhao, L | 1 |
| Aparicio, AM; Broom, B; Chang, W; Corn, PG; Dobashi, M; Efstathiou, E; Karanika, S; Karantanos, T; Lee, HS; Lee, JS; Li Ning Tapia, EM; Li, L; Maity, SN; Navone, N; Park, S; Ren, C; Shah, PK; Takahiro, H; Thompson, TC; Troncoso, P; Wang, J; Xiao, L; Yang, G; Yin, J; Zhang, W | 1 |
| Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M | 1 |
| Keszenman, DJ; Lafon-Hughes, L; Liddle, P; Perini, V; Schacke, M; Vilchez-Larrea, S | 1 |
| Huang, SH; Liu, F; Meng, LQ; Tang, YX; Wang, SP; Wu, SQ; Xu, YG; Zhu, QH | 1 |
| Huang, L; Huang, SH; Lin, QW; Tang, YX; Wang, SP; Wu, SQ; Xu, YG | 1 |
6 other study(ies) available for thiophenes and olaparib
| Article | Year |
|---|---|
Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Topics: Analysis of Variance; Cell Cycle Checkpoints; Checkpoint Kinase 1; DNA Repair; Drug Combinations; Flow Cytometry; Histones; Humans; Immunoblotting; Intestinal Mucosa; Mutation; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Thiophenes; Tumor Suppressor Protein p53; Urea | 2011 |
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Topics: Animals; BRCA1 Protein; Carrier Proteins; Castration; Cell Cycle Checkpoints; DNA Damage; DNA-Binding Proteins; Humans; Male; Mice; Mice, Nude; Nuclear Proteins; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-myb; Receptors, Androgen; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2014 |
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disulfiram; Glutamates; Humans; Imidazoles; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Phthalazines; Piperazines; Prostate; Spheroids, Cellular; Thiophenes; Topotecan; Tumor Cells, Cultured; Urea | 2016 |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Bleomycin; Chlorocebus aethiops; Chromones; DNA Ligase ATP; DNA Repair; DNA-Activated Protein Kinase; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Morpholines; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrimidines; Pyrones; Schiff Bases; Thiophenes; Vero Cells | 2020 |
FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.
Topics: Cell Cycle; Cell Division; Cell Line, Tumor; DNA Damage; Forkhead Box Protein M1; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Thiophenes; Triple Negative Breast Neoplasms | 2021 |
FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
Topics: Animals; Apoptosis; BRCA1 Protein; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Comet Assay; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Signal Transduction; Thiophenes | 2022 |